| Authors: |
Lopez-Leon S; Quantitative Safety & Epidemiology, Novartis Pharmaceuticals, East Hanover, New Jersey, USA.; Rutgers Center for Pharmacoepidemiology and Treatment Science, Rutgers University, New Brunswick, New Jersey, USA., Wen X; Health Outcomes Research, Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, USA., Gaitonde S; Rutgers Center for Pharmacoepidemiology and Treatment Science, Rutgers University, New Brunswick, New Jersey, USA., Afonso AS; Eli Lilly Nederland BV, Utrecht, the Netherlands., Colas S; Epidemiology and Benefit Risk, Global R&D, Sanofi, Toronto, Canada., DiSantostefano RL; Janssen Research & Development LLC, Titusville, New Jersey, USA., Kürzinger ML; Epidemiology and Benefit Risk, Global R&D, Sanofi, Paris, France., Le Noan-Lainé M; Eli Lilly and Company, Cork, Ireland., Mitter VR; University of Oslo, Oslo, Norway.; Applied Research and Development, Division of Midwifery, Department of Health Professions, Bern University of Applied Sciences, Bern, Switzerland., Murray G; Janssen Research & Development LLC, Titusville, New Jersey, USA., Sabidó M; Department of Epidemiology, Merck Healthcare KGaA, Darmstadt, Germany., Scotto J; Bristol Myers Squibb, Princeton, New Jersey, USA., Jacobson MH; Janssen Research & Development LLC, Titusville, New Jersey, USA., Bromley RL; Division of Neuroscience, University of Manchester, Manchester, UK.; Royal Manchester Children's Hospital, Manchester University Hospitals NHS Foundation Trust and Manchester Academic Health Sciences Centre, Manchester, UK., Sarayani A; Janssen Research & Development LLC, Titusville, New Jersey, USA. |
